In 2006, the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase in which nine patients with recurrent glioblastoma multiforme were administered THC.

Background: Patients had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumour progression. The primary end point of the study was to determine the safety of intracranial THC administration.

You can read the full article here =>https://www.nature.com/articles/6603236